Australia Pharmaceuticals and Healthcare Report Q3 2013:Life Sciences Market Research Reports

Life Sciences Market Research Reports

Australia Pharmaceuticals and Healthcare Report Q3 2013 May 8th 2013, 00:00 BMI View: As a developed market, Australia represents opportunities for risk averse pharmaceutical investors, given its ageing and generally affluent population. Importantly, the government is implementing cost-cutting measures to cope with escalating healthcare costs, therefore generic drugmakers will stand to benefit from the patented to generic drug switch. However, given that generic costs is higher in Australia as compared to other developed countries, a downside risk to the view is the lack of generic substitution, given no apparent benefits to patients. Headline Expenditure Projections ? Pharmaceuticals: AUD13.47bn (US$13.95bn) in 2012 to AUD13.95bn (US$13.94bn) in 2013; +3.6% in local currency terms … Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=94949. Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/australia-pharmaceuticals-and-healthcare-report-q3-2013-market-report.html.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions